GDF11
A growth factor once hailed as a rejuvenating 'young blood' molecule, whose headline mouse results were challenged within two years
GDF11 is a circulating protein of the TGF-β family, closely related to myostatin. In 2013 and 2014 Harvard groups reported that restoring it reversed heart and muscle ageing in old mice; other laboratories found the measurements confounded and GDF11 harming muscle repair. It has never been tested in people.
What is it?
GDF11 became famous through parabiosis, the surgical joining of an old and a young mouse so they share a circulation. A Harvard team found old hearts shrank back toward a youthful size, identified GDF11 as a blood factor that falls with age, and reported that giving it to old mice reproduced the effect. A second paper extended the claim to muscle stem cells and exercise capacity.
The story then turned. GDF11 and myostatin are so similar that the assays used could not tell them apart. A Novartis team reported GDF11 rising with age and blocking muscle regeneration; a Mayo Clinic study in people found no decline with age and linked higher GDF11 to frailty. The original group replied that the opposing antibody also detected immunoglobulin.
Newer human measurement has not settled the direction. A 2026 study found GDF11 higher in older adults and higher still with sarcopenia, the reverse of the mouse claim. In 11,609 people at cardiovascular risk, low levels of an aptamer-measured GDF11/8 signal predicted heart events and death strongly, but the same aptamer also reads myostatin, the old assay problem in a new form.
Animal work is just as split. Recombinant GDF11 improved stroke recovery in rats across six blinded studies, and GDF11-releasing cells resolved age-related lung fibrosis in mice; yet another mouse study found GDF11 itself caused lung injury and fibrosis. Smaller human studies tie low levels to childhood asthma, worse outcomes after heart attack and diabetic artery thickening.
No study has given GDF11 to a person. Everything below is animal work or measurement of the protein in human blood.
Mechanism of Action
GDF11 is a protein closely related to myostatin (GDF8); it signals through Smad2/3, and most assays struggle to tell the two apart.
Smad2/3 signalling
It signals through ALK5-Smad2/3, which in mouse lungs drove injury and fibrosis.
Measurement problem
Antibody and aptamer assays cross-react with myostatin, which is why human studies disagree on whether it falls or rises with age.
Recovery in animals
Recombinant GDF11 improved stroke recovery in rats, but no human has received it.
Published Research
Animal studies on both sides of the dispute and the human blood studies, read from PubMed abstracts on October 4, 2026.
Cardiovascular risk in 11,609 patients
In 11,609 people at cardiovascular risk, low aptamer-measured GDF11/8 strongly predicted cardiovascular events (hazard ratio 0.43) and death (0.33), replicating more weakly with a GDF8-selective aptamer; low levels also predicted dementia in a second cohort of 4,110.
Higher with age and sarcopenia
Circulating GDF11 was higher in older than younger adults and higher again with sarcopenia, while GDF11 gene expression in muscle did not change with sarcopenia or exercise.
Genetic associations
Biobank genome-wide analyses linked GDF11 genetic variants and predicted expression to asthma, immune function, lung function and thyroid traits.
Childhood asthma
Children with asthma had lower serum GDF11, lower still during exacerbations, and higher levels went with better lung function and fewer exacerbations.
After heart attack
In STEMI patients treated with PCI, lower pre-procedure GDF11 predicted worsening ischaemic mitral regurgitation and heart failure.
Type 2 diabetes and carotid arteries
Elderly people with type 2 diabetes had lower GDF11 than controls, and higher GDF11 went with less carotid wall thickening.
Sleep apnoea
In 56 men with obstructive sleep apnoea and 27 controls, GDF11 did not differ, while GDF15 was 1.3 times higher.
A rare human mutation
A rare loss-of-function GDF11 mutation in a patient with developmental, neural and cardiovascular features was modelled in cells and corrected with prime editing, supporting haploinsufficiency.
The original heart paper
Four weeks of shared circulation with young mice reversed cardiac hypertrophy in old mice. Proteomics identified GDF11 as a young-blood factor that declines with age, and restoring it to youthful levels reproduced the regression of heart enlargement.
Muscle stem cells and strength
Raising GDF11 in aged mice by parabiosis or recombinant protein restored function and DNA integrity in muscle stem cells and improved muscle structure, strength and endurance.
The Novartis counter-paper
The earlier claims could not be reproduced, and the reagents used were not specific to GDF11. With a GDF11-specific immunoassay, levels trended upward with age in rats and humans; GDF11 inhibited muscle regeneration and satellite cell expansion in mice, like myostatin.
An assay that cross-reacts
The ELISA used earlier cross-reacted between GDF11 and myostatin. Estimated GDF11 levels were almost 500 times lower than myostatin's, too low to matter at the shared receptor, the authors argued.
The original group replies
Circulating GDF11/8 declined with age in mice, rats, horses and sheep; the Novartis rise was attributed to the antibody detecting immunoglobulin. GDF11 lowered cardiac mass in young and old mice within nine days.
Mass spectrometry in people
A specific LC-MS/MS assay found myostatin, not GDF11, declining with age in healthy men and neither changing in women. In older adults with severe aortic stenosis, higher GDF11 went with frailty, diabetes and prior heart disease, and predicted rehospitalisation after valve surgery.
Worse muscle recovery in old rats
In older rats with a complex muscle injury, GDF11 treatment increased fibrosis and weakened functional recovery compared with vehicle.
Larger heart attacks
Boosting circulating GDF11 before induced heart attacks enlarged infarct size in mice of any age by accelerating cell death; in people, higher circulating GDF11 was associated with larger infarcts.
Stroke recovery in rats
Across 6 blinded studies run by independent contract labs, recombinant GDF11 at 0.1 to 4 mg/kg given 24 to 72 hours after stroke improved sensorimotor recovery in rats and lowered CRP.
Lung injury in mice
In mice, GDF11 caused lung injury, inflammation and fibrosis through ALK5-Smad2/3 signalling, while a GDF11 propeptide reduced bleomycin-induced fibrosis.
Cell-delivered GDF11 in aged lungs
In a mouse model of age-related pulmonary fibrosis, transplanted cells engineered to release GDF11 on demand reduced senescence and resolved fibrosis.
Dosing Data
GDF11 has never been given to people. The only dose below comes from rat stroke studies.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Side Effects & Contraindications
Reported Side Effects
No human safety data exist; these are signals from animals and human association studies.
Contraindications & Cautions
None established, because it has never been given to people in a study.
Legal Status
Not approved anywhere; never tested in a clinical trial.
Frequently Asked Questions
?Does GDF11 reverse ageing?
In two 2013-2014 mouse studies it appeared to; later studies found the measurements unreliable and reported GDF11 harming muscle repair. No human study has tested it.
?Does GDF11 decline with age in humans?
A 2016 mass-spectrometry study found no decline in healthy men or women; the question was clouded by assays that could not separate GDF11 from myostatin.
?Is GDF11 a peptide?
No. It is a 109-residue protein of the TGF-β family that works as a dimer, closely related to myostatin.
?Has anyone taken GDF11 in a trial?
No registered or published human trial was found.
?Is low GDF11 bad?
In a study of 11,609 people at cardiovascular risk, low levels of an aptamer-measured GDF11/8 signal predicted heart events and death. That aptamer also reads myostatin, so the result cannot be pinned to GDF11 alone.
?Does GDF11 help or harm in animals?
Both have been reported: it improved stroke recovery in rats and, delivered by engineered cells, resolved lung fibrosis in aged mice, but in another mouse study GDF11 itself caused lung injury and fibrosis.
References
- [pubmed] Loffredo FS, et al. "Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy." Cell, 2013;153(4):828-39. PMID: 23663781.
- [pubmed] Sinha M, et al. "Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle." Science, 2014;344(6184):649-52. PMID: 24797481.
- [pubmed] Egerman MA, et al. "GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration." Cell Metab, 2015;22(1):164-74. PMID: 26001423.
- [pubmed] Rodgers BD, et al. "Reduced Circulating GDF11 Is Unlikely Responsible for Age-Dependent Changes in Mouse Heart, Muscle, and Brain." Endocrinology, 2015;156(11):3885-8. PMID: 26372181.
- [pubmed] Poggioli T, et al. "Circulating Growth Differentiation Factor 11/8 Levels Decline With Age." Circ Res, 2016;118(1):29-37. PMID: 26489925.
- [pubmed] Schafer MJ, et al. "Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease." Cell Metab, 2016;23(6):1207-1215. PMID: 27304512.
- [pubmed] Zhou Y, et al. "GDF11 Treatment Attenuates the Recovery of Skeletal Muscle Function After Injury in Older Rats." AAPS J, 2017;19(2):431-437. PMID: 27924614.
- [pubmed] Kraler S, et al. "Circulating GDF11 exacerbates myocardial injury in mice and associates with increased infarct size in humans." Cardiovasc Res, 2023;119(17):2729-2742. PMID: 37742057.
- [pubmed] Walker RG, et al. "Activated GDF11/8 subforms predict cardiovascular events and mortality in humans." Nat Commun, 2025;16(1):6534. PMID: 40664633.
- [pubmed] Chen R, et al. "Elevated circulating GDF11 and its role in age-related sarcopenia: insights from clinical, transcriptomic, and in vitro analyses." Front Aging, 2026;7:1736069. PMID: 41822302.
- [pubmed] Strosahl J, et al. "Novel insights into the pleiotropic health effects of growth differentiation factor 11 gained from genome-wide association studies in population biobanks." BMC Genomics, 2024;25(1):837. PMID: 39237910.
- [pubmed] Che Y, et al. "Association of serum growth differentiation factor 11 with asthma severity, inflammation, and airway remodeling in pediatric patients." Front Med (Lausanne), 2026;13:1872411. PMID: 42548683.
- [pubmed] Ye J, et al. "Correlation Between Serum GDF11 Levels and the Progression of Ischemic Mitral Regurgitation and Long-term Prognosis in Patients with ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention." J Cardiovasc Transl Res, 2026;19(1):15. PMID: 41642484.
- [pubmed] Wang X, et al. "Serum BAFF and GDF11: cross-sectional associations with glycolipid metabolism and subclinical carotid artery wall thickening in elderly type 2 diabetes patients." Front Cardiovasc Med, 2026;13:1891416. PMID: 42682957.
- [pubmed] Madaeva IM, et al. "GDF11 (Protein of Juvenility) and GDF15 (Protein of Senility) in the Plasma of Patients with Sleep Apnea Syndrome: a Pilot Study." Bull Exp Biol Med, 2024;177(2):274-277. PMID: 39090465.
- [pubmed] Congdon ST, et al. "Investigating and correcting a rare pathogenic mutation in GDF11." HGG Adv, 2026;7(1):100559. PMID: 41414712.
- [pubmed] Cohen OS, et al. "Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke." Stroke, 2025;56(4):996-1009. PMID: 39909827.
- [pubmed] Li Q, et al. "Growth Differentiation Factor 11 Evokes Lung Injury, Inflammation, and Fibrosis in Mice through the Activin A Receptor Type II-Like Kinase, 53kDa-Smad2/3 Signaling Pathway." Am J Pathol, 2024;194(11):2036-2058. PMID: 39147236.
- [pubmed] Guo L, et al. "GDF11-secreting cell transplant efficiently ameliorates age-related pulmonary fibrosis." Mol Ther, 2025;33(10):5131-5148. PMID: 40676836.
Sources & Citations
Studies were read from their PubMed abstracts. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.